Skip to content

Observation of the efficacy of floating needle combined with suboccipital muscle group release technology in the treatment of vertebral artery cervical spondylosis and its effect on hemodynamics

Observation of the efficacy of floating needle combined with suboccipital muscle group release technology in the treatment of vertebral artery cervical spondylosis and its effect on hemodynamics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096533
Enrollment
Unknown
Registered
2025-01-24
Start date
2025-01-27
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral Artery-Type Cervical Spondylosis

Interventions

Floating Needle Group:The patient is seated and first palpated to identify myofascial trigger points (MTrPs), the main trigger points of vertebral artery cervical spondylosis include sternocleidomasto
Suboccipital Muscle Release Group:Using the thumbs of both hands, apply moderate, sustained pressure to the suboccipital muscles for 5-10 seconds, then gradually relax. This process is repeated severa

Sponsors

Fuyong People's Hospital, Bao'an District, Shenzhen City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for vertebral artery-type cervical spondylosis; (2) Aged between 18 and 60 years; (3) Able to actively cooperate and complete the entire trial treatment course; (4) Has not received any other treatments that could interfere with the outcomes of this study within 7 days prior to enrollment; (5) Has no history of needle phobia or allergic reactions to acupuncture; (6) Voluntarily signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with cervical conditions such as osteoporosis, tuberculosis, or tumors; (2) Patients with abnormal vertebral artery blood flow velocity caused by other primary diseases such as diabetes, hypertension, or arteriosclerosis; (3) Patients with concurrent organ failure or severe primary diseases of the hematopoietic or endocrine systems; (4) Patients with comorbidities such as dementia, Parkinson's disease, or conditions involving altered consciousness or mental disorders; (5) Women who are pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Vertigo Disorder Score;

Secondary

MeasureTime frame
Visual analogue pain score;Mean Vertebral Artery Blood Flow Velocity;Mean Basilar Artery Blood Flow Velocity;

Countries

China

Contacts

Public ContactLei Bo

Fuyong People's Hospital, Bao'an District, Shenzhen City

szleidoctor@163.com+86 151 0755 0352

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026